Incyte Genomics, Inc. v. Invitrogen Corporation

I'll research this case thoroughly before drafting. Let me start with several searches.

Let me research the two patents and the broader litigation context.

Let me pin down the docket, judge, and ultimate disposition.

Case Overview and Background

The parties. Incyte Genomics, Inc. (Palo Alto, CA; now Incyte Corporation, Nasdaq: INCY) was, at the time of filing, a genomics information and intellectual-property company — it had built one of the largest commercial portfolios of human gene patents and the LifeSeq/GEM databases, and by late 2001 was pivoting toward therapeutic discovery and information licensing. It was not an NPE/PAE: the Stanford Patent Litigation (NPE) database classifies Incyte in this case as both a "product company" and, because of its licensing arrangement with the patent owner, under the "University/Government/Non-profit" category (Stanford NPE database). The two patents asserted here are owned by The Board of Trustees of the Leland Stanford Junior University and were exclusively licensed to Incyte; the docket caption reads "Incyte Genomics, Inc., et al. v. Invitrogen Corp.," and Stanford appears as a party to this case in the Stanford database, which indicates Stanford was joined as co-plaintiff on its own patents — though I could not confirm that directly from PACER. Defendant Invitrogen Corporation (Carlsbad, CA) was, and through its successors remains, a life-sciences reagent and research-tools operating company (it merged with Applied Biosystems in 2008 to form Life Technologies, acquired by Thermo Fisher Scientific in 2014).

The patents and the accused technology. U.S. Patent No. 5,807,522 ("Methods for fabricating microarrays of biological samples," issued Sept. 15, 1998, inventors Patrick O. Brown and Tidhar Dari Shalon, assigned to Stanford) claims the foundational "spotting" method for making cDNA microarrays: loading an analyte-specific reagent into an open elongate capillary channel and tapping the tip against a solid support with an impulse sufficient to break the meniscus and deposit a defined volume, repeated to build an array — including embodiments with ~100 or ~1,000+ discrete polynucleotide regions per cm² (patent text). U.S. Patent No. 6,110,426 (issued Aug. 29, 2000, Shalon and Brown, same assignee and title) is a continuation of the same family (continuation of App. No. 08/477,809, which issued as the '522) with an essentially parallel disclosure covering the method/apparatus (uspto.report). The complaint, filed November 21, 2001, actually asserted sixteen patents — eleven "gene patents," three RNA-amplification/gene-expression patents (including the Eberwine patents '785 and '636, licensed from Layton Bioscience), and these two Stanford microarray patents — seeking a permanent injunction, damages, treble damages for willful infringement, fees, costs, and interest (Incyte 8-K, Nov. 21, 2001). Our case tracking scopes the matter to the two Stanford microarray patents, which were the flagship platform IP. I could not verify from any retrievable source which specific Invitrogen products or services were named as infringing — the complaint itself is not in the public materials I could reach, so any description of the accused instrumentalities would be speculation; given the mix of asserted patents, the accused technology plausibly spanned Invitrogen's nucleic-acid reagents, amplification products, and array-related offerings, but that is inference, not a sourced finding.

Procedural posture and venue. The action was filed in the U.S. District Court for the Southern District of California as No. 3:01-cv-02141 (the "3:" prefix denotes the court's San Diego division). Venue significance is straightforward and strong: Invitrogen's principal place of business was in Carlsbad, within the Southern District, so the defendant was at home in the district. I could not verify the assigned district judge from available sources. The case was one front in multi-front litigation between the two companies: on the same day Incyte answered an Invitrogen complaint pending in the District of Delaware (asserting seven counterclaims including declaratory relief, implied license, estoppel, laches, and patent misuse) and moved to transfer that Delaware action to the District of Maryland, where Invitrogen was already a party to three infringement actions involving the same patents-in-suit (8-K). The ultimate disposition of Incyte v. Invitrogen is not verified in the sources I could retrieve; I found no reported merits opinion, verdict, or public settlement terms, so I cannot state how (or whether) the S.D. Cal. action was resolved.

Why it is notable. The '522/'426 family is genuinely foundational — the Brown/Shalon two-color cDNA microarray spotting technique underpins the academic and commercial microarray era, and the '522 was described as broadly covering methods of printing microarrays at densities greater than 100 polynucleotides/cm², enabling arrays of 10,000+ elements (BIOTECH Patent News via TheFreeLibrary). Incyte monetized the Stanford license widely, granting microarray-manufacturing licenses to Merck (internal array manufacturing), Chiron, Gene Logic, GeneMachines, and spotting-pin maker Point Technologies (TheFreeLibrary; Laboratory Talk), and the same two patents appear repeatedly as incorporated-by-reference prior art in later array patents — evidence of their centrality. The case is also a useful marker of the early-2000s genomics IP arms race: Incyte simultaneously sued Invitrogen, litigated with Affymetrix (settled December 2001 with cross-licenses covering Affymetrix's '934/'305/'992/'928/'193 microarray patents and Incyte's RNA-amplification patents), and settled with Gene Logic (8-K). Two caveats for market context: (1) there is no IPR linkage here — inter partes review did not exist until the 2011 America Invents Act, a decade after this case, so the modern PTAB/IPR dynamic is inapplicable; and (2) Incyte was asserting its own and exclusively licensed operating-company IP against a competitor in its market, which distinguishes this from the later NPE/PAE assertion pattern the same Stanford database was built to track. I recommend confirming the docket-level outcome (dismissal, settlement, or transfer) via PACER/RECAP before relying on any final-disposition statement, as that remains the one material gap in the public record retrievable here.

I'll research this case systematically, starting with the basic docket and case outcome.

Let me dig deeper into the specific case docket and the related litigation.

Let me look at the specific S.D. Cal. case docket and disposition records.

I've hit my research-step limit, so the following synthesis is built from what I was able to verify, with clear flags where the record is thin. One important framing note up front: this S.D. Cal. case (Incyte v. Invitrogen, 3:01-cv-02141) was only one half of a two-front war between these parties, and the docket for the S.D. Cal. side is sparse in the public sources I could reach. I could not pull the PACER docket directly, so several procedural milestones below are inferred from the parties' SEC disclosures and one secondary-source citation, and I label them as such.

Verified facts at a glance

• The S.D. Cal. complaint was filed 2001-11-21, asserting sixteen patents, of which only two relate to microarray fabrication: U.S. Pat. Nos. 5,807,522 (issued 1998-09-15) and 6,110,426 (issued 2000-08-29), both titled "Methods for Fabricating Microarrays of Biological Samples." The other fourteen covered gene patents and RNA amplification/gene-expression patents. Source: Incyte SEC 8-K / 10-Q, "Item 5," Nov. 2001 (https://investor.incyte.com/node/9266/html).
• Relief sought: permanent injunction, damages, treble damages for willful infringement, fees, costs, interest.
• The case ended by stipulation and order of dismissal dated 2004-02-10 (S.D. Cal., No. 01-2141). Source: cited as "Stipulation and Order of Dismissal, Incyte Genomics Inc., No. 01-2141 (S.D. Cal. Feb. 10, 2004)" in a scholarly footnote referencing Incyte's FY2003 Form 10-K (Dec. 31, 2003).

Chronology

2001-10-17 — Parallel Delaware action filed. Invitrogen filed suit against Incyte in D. Del. (Invitrogen Corp. v. Incyte Genomics, Inc., No. 01-692-SLR), asserting three RNase H⁻ reverse-transcriptase patents (U.S. 5,244,797; 5,668,005; 6,063,608) — a wholly different technology from the microarray patents. Source: D. Del. Memorandum Order, 2002 (https://corpora.tika.apache.org/base/docs/govdocs1/853/[853648](/patent/853648).pdf).

2001-11-21 — Complaint filed in S.D. Cal. (the case at bar). Incyte sued Invitrogen on sixteen patents including the two microarray patents, captioned as No. 3:01-cv-02141. The same day, Incyte filed its answer and seven counterclaims in the Delaware case (declaratory judgment of invalidity/noninfringement, implied license, estoppel, laches, and patent misuse) and moved to transfer the Delaware case to the District of Maryland. Invitrogen's response to the S.D. Cal. complaint was calendared for 2001-12-11.

2001-12-21 and 2002-03-07 — Amended complaints. Incyte's disclosures state the S.D. Cal. complaint was "amended on December 21, 2001 and March 7, 2002." I could not verify the substance of either amendment (e.g., whether patents or claims were added/dropped) from the sources retrieved.

2002-05-01 — Delaware transfer motion denied. In a Memorandum Order, Judge Sue L. Robinson denied Incyte's § 1404(a) motion to move the Delaware action to Maryland, finding the private-interest factors did not favor transfer. Invitrogen Corp. v. Incyte Genomics, Inc., No. 01-692-SLR, 2002 WL 883963 (D. Del. May 1, 2002). This is the Delaware case, not S.D. Cal., but it is the only contemporaneous contested ruling I could verify between these parties.

2003-02 — Delaware counterclaim added. Incyte added a unfair-business-practices counterclaim in the Delaware action. (Incyte 10-Q.)

2003-06-18 — Licensing activity on the two microarray patents. Incyte sublicensed U.S. 5,807,522 and 6,110,426 to Point Technologies (spotting-pin maker), following an earlier license to GeneMachines. https://laboratorytalk.com/article/52767/nucleic-acid-array-patent-deal and Biocentury report. Strategically, this shows the two patents were being actively monetized by licensing while the S.D. Cal. suit was pending.

2004-02-10 — S.D. Cal. dismissed by stipulation. The S.D. Cal. action (No. 01-2141) was terminated by a stipulation and order of dismissal. I could not verify from the retrieved sources whether the dismissal was with or without prejudice, whether it was tied to a settlement or cross-license, or whether it accompanied any payment. The FY2003 10-K reference suggests the parties characterized it as a resolution of that docket.

2004-02 — Delaware action stayed. In February 2004, the D. Del. court stayed all proceedings pending disposition of an appeal in a related case that had invalidated the same RNase H⁻ patents asserted against Incyte.

2005-11-18 — Federal Circuit vacates the invalidity judgment. The Federal Circuit vacated the judgment invalidating those patents and remanded the related case.

2006-01-25 — Delaware stay lifted. The D. Del. court lifted the stay limited to discovery on Incyte's license defense, with further motion practice expected. After 2006, publicly available Incyte disclosures no longer flag this dispute prominently — I could not verify an ultimate Delaware judgment or settlement from the retrieved sources.

What I could NOT verify (stated plainly)

• Answer/counterclaims in the S.D. Cal. case. No source retrieved confirms Invitrogen's answer or any counterclaims it filed in No. 01-2141 itself.
• Pre-trial motions in S.D. Cal. No motion to dismiss, transfer, stay, or summary-judgment ruling in No. 01-2141 was retrievable. The case appears to have terminated on a stipulated dismissal before any merits ruling.
• Markman / claim construction. No Markman order or hearing for the microarray patents in this case was found. On the record available, the case appears not to have reached claim construction.
• Discovery milestones, trial, verdict, post-trial motions (JMOL/new trial/fees). Nothing retrieved. The stipulated dismissal at 2004-02-10 strongly implies there was no trial, verdict, or fee award in this docket.
• Settlement terms. Unknown. If the dismissal was part of a global resolution of the Incyte–Invitrogen disputes, the terms were not disclosed in the sources I could reach.
• Parallel PTAB proceedings. I found no IPR or PGR on U.S. 5,807,522 or 6,110,426. As a legal matter, IPR/PGR did not exist during this litigation — they were created by the AIA and became available 2012-09-16 — so no IPR/PGR could have affected this 2001–2004 case. Any post-2012 PTAB activity would postdate the litigation and would need separate verification.

Separate litigation not to conflate with this case

• Incyte v. Affymetrix settled 2001-12-21, involving Affymetrix's microarray patents (5,445,934; 5,744,305; 5,800,992; 5,871,928; 6,040,193) and Incyte's RNA-amplification patents — not the two microarray-fabrication patents at issue here.
• Invitrogen Corp. v. Incyte Genomics, Inc., No. 01-692-SLR (D. Del.), on the RNase H⁻ reverse-transcriptase patents (5,244,797; 5,668,005; 6,063,608) — the stayed/remanded action described above.

If you need the definitive procedural history for No. 01-2141 (exact dismissal language, prejudice, and any accompanying agreement), that would require a direct PACER pull of the S.D. Cal. docket, which I was not able to complete within this session — I'd rather flag that gap than guess at the docket entries.

I'll research plaintiff-side counsel for Incyte in this S.D. Cal. action, starting with broad docket-focused searches.

Let me try the CourtListener/RECAP docket and firm-specific searches.

Good — I found a key outcome detail (Jan. 2004 settlement/license; Feb. 9, 2004 dismissal order). Now let me hunt specifically for counsel names via docket and related opinions.

Plaintiff-side counsel of record — not verifiable from the sources I could reach in this session

I have to lead with the honest answer: *I could not identify, and therefore cannot name, any attorney who represented Incyte Genomics (or co-plaintiff Stanford) in Incyte Genomics, Inc., et al. v. Invitrogen Corp., No. 3:01-cv-02141 (S.D. Cal.).* I located no signature block, appearance, stipulation, or opinion in this docket that carries a plaintiff-side attorney's name. Per the operating rules, I am flagging that gap rather than filling it with plausible-sounding names. Below I set out (a) what the record does establish that bears on counsel identification, (b) exactly why the names aren't retrievable, and (c) the precise documents and searches that would resolve it.

Why this docket is unusually thin on counsel

• The case produced no merits opinion. It terminated by stipulated dismissal on a settlement/license, so there is no published or unpublished court decision naming "Counsel for Plaintiff" in a caption block — which is how counsel is usually recoverable for 2001–2004 cases.
• The docket predates RECAP coverage. Electronic filing in S.D. Cal. and RECAP harvesting post-date the 2001–2004 window; the CourtListener queries I ran did not surface a gov.uscourts.casd docket for 3:01-cv-02141. (The Stanford NPE Litigation Database confirms the case exists and its caption but contains no counsel field: Incyte Genomics, Inc. party page; patent '522 page.)
• Incyte's SEC disclosures name the litigation but never outside counsel. Incyte's contemporaneous 8-Ks and 10-Ks describe the sixteen asserted patents, the relief sought, the willful-infringement/treble-damages theory, the January 2004 settlement and license, and the court-ordered dismissal — but they do not list law firms. (Incyte 8-K, Nov. 21, 2001; Incyte FY2004 Form 10-K, Item 3, stocklight PDF.)

Two facts that bear directly on who the plaintiff-side counsel were

1. The caption has an "et al." — consistent with Stanford as a co-plaintiff. The docket caption is "Incyte Genomics Inc, et al v. Invitrogen Corp" (Stanford NPE database, links above). The '522 and '426 patents are owned by The Board of Trustees of the Leland Stanford Junior University and exclusively licensed to Incyte. That structure ordinarily means two separate plaintiff-side legal teams: Incyte's litigation counsel (asserting its exclusive-licensee standing and damages) and Stanford's own counsel (the patent owner — typically Stanford's Office of the General Counsel and/or its outside patent-litigation firm). I could not confirm from any retrieved filing that Stanford actually appeared as a named party in the S.D. Cal. action; treat that as a documented-but-not-primary-source inference from the caption and the Stanford database.
2. The case resolved by agreement, not adjudication. Incyte's FY2004 10-K states: "In January 2004, we reached an agreement to settle our suit against Invitrogen, with Invitrogen entering into a license agreement with us. On February 9, 2004, the Court ordered dismissal of the case." (10-K.) The stipulation of dismissal — which the parties' counsel necessarily signed — is the single most likely document to contain the names of plaintiff-side counsel of record, alongside the original complaint's signature block and any notices of appearance.

Flag on a prior section: the earlier "Key legal developments" section dated the dismissal Feb. 10, 2004, citing a scholarly footnote; Incyte's own 10-K says the court ordered dismissal Feb. 9, 2004 (stipulation executed around then). Minor, but worth reconciling when the docket is pulled.

Where the names will be, and how to get them

Because I could not complete a PACER pull, these are the specific documents/sources that would give a definitive, citable answer:

Leads I found, explicitly unverified for this case

• Mark R. Wicker (San Diego). A San Diego life-sciences lawyer whose published bio states he "advised Incyte Genomics in creating its early genomics business model" (Best Lawyers profile). That is described as business-model/licensing work, not litigation in this docket — so he is a candidate for the transactional side of the Incyte–Invitrogen relationship (relevant because the 2004 resolution was a license, not a judgment), but I have no evidence he appeared in 3:01-cv-02141, and I am not asserting that he did.
• The vendor-side licensing activity around the case (GeneMachines, Point Technologies sublicenses in 2003) shows Incyte's patent counsel were actively transacting while the suit was pending, but those announcements do not name litigation counsel either (Laboratory Talk).

Bottom line

• Plaintiff(s): Incyte Genomics, Inc. (and, per the caption, likely Stanford as co-plaintiff).
• Counsel of record for plaintiff(s): Not identified / not verifiable from retrievable public sources. No attorney name, firm, or role can be stated without fabrication.
• Defendant-side counsel and plaintiff-side counsel both require a PACER pull of the S.D. Cal. docket (and, for corroboration, the D. Del. 01-692 docket) — the filings are not sealed as far as the record shows; they are simply not in the free online corpora for a 2001–2004 S.D. Cal. case. I could not complete that pull within this session.

If you want, I can draft the exact PACER query strings (case number, the D.I. numbers above, and the party-name search terms) so the next pass can retrieve the complaint, appearance entries, and the 2004 stipulation and extract the signature blocks directly.

I'll research the counsel of record for Invitrogen in this case using multiple targeted searches.